SOPHiA GENETICS (NASDAQ:SOPH) Insider Zhenyu Xu Sells 2,400 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 2,400 shares of SOPHiA GENETICS stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $4.87, for a total transaction of $11,688.00. Following the completion of the sale, the insider owned 644,952 shares in the company, valued at $3,140,916.24. This trade represents a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenyu Xu also recently made the following trade(s):

• On Monday, April 6th, Zhenyu Xu sold 2,700 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total transaction of $13,095.00.
• On Thursday, March 19th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.78, for a total transaction of $2,906.24.

SOPHiA GENETICS Stock Down 0.3%

Shares of NASDAQ SOPH traded down $0.01 during midday trading on Wednesday, reaching $4.89. The company’s stock had a trading volume of 64,929 shares, compared to its average volume of 188,371. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. SOPHiA GENETICS SA has a fifty-two week low of $2.58 and a fifty-two week high of $5.70. The stock has a market capitalization of $334.64 million, a price-to-earnings ratio of -9.58 and a beta of 1.04. The stock has a 50 day simple moving average of $4.78 and a 200-day simple moving average of $4.68.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The business had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. Equities research analysts predict that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently made changes to their positions in the company. XTX Topco Ltd bought a new position in shares of SOPHiA GENETICS in the fourth quarter valued at $55,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS in the fourth quarter valued at $54,000. Archon Capital Management LLC grew its stake in shares of SOPHiA GENETICS by 3.4% in the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock valued at $2,061,000 after buying an additional 14,342 shares in the last quarter. Renaissance Technologies LLC boosted its position in SOPHiA GENETICS by 169.5% during the fourth quarter. Renaissance Technologies LLC now owns 83,000 shares of the company’s stock worth $388,000 after purchasing an additional 52,200 shares during the period. Finally, Polen Capital Management LLC bought a new position in SOPHiA GENETICS during the fourth quarter worth $102,000. 31.59% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Guggenheim raised their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, BTIG Research reissued a “buy” rating and issued a $7.00 target price on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.